+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biodesix Inc (BDSX) - Product Pipeline Analysis, 2023 Update

  • PDF Icon

    Company Profile

  • 44 Pages
  • June 2023
  • GlobalData
  • ID: 5740073
Biodesix Inc (Biodesix) is a molecular diagnostics company which discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests in oncology for patients and doctors to enable precision medicine. These tests are used for early detection of diseases, diagnosis accuracy, disease monitoring and also provide improved therapeutic guidance for cancer patients. Biodesix’s product portfolio includes GeneStrat, a gene panel of clinically actionable mutations for tumor profiling for patients with advanced lung cancer; and VeriStrat, a serum proteomic test for patients with non-small cell lung cancer. The company collaborates with leading researchers to develop companion diagnostics for use with therapeutic agents and work in partnership with biotechnology and pharmaceutical companies such as Aveo Oncology and Biognosys. Biodesix is headquartered in Boulder, Colorado, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Biodesix Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Biodesix Inc Company Overview
  • Biodesix Inc Company Snapshot
  • Biodesix Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Biodesix Inc - Pipeline Analysis Overview
  • Biodesix Inc - Key Facts
  • Biodesix Inc - Major Products and Services
  • Biodesix Inc Pipeline Products by Development Stage
  • Biodesix Inc Ongoing Clinical Trials by Trial Status
  • Biodesix Inc Pipeline Products Overview
  • 52-Gene Panel Based Companion Diagnostic
  • 52-Gene Panel Based Companion Diagnostic Product Overview
  • AI-Based Algorithm - COVID-19
  • AI-Based Algorithm - COVID-19 Product Overview
  • Biodesix Collection Device
  • Biodesix Collection Device Product Overview
  • Companion Diagnostic Test - NSCLC
  • Companion Diagnostic Test - NSCLC Product Overview
  • HIV Diagnostic Test
  • HIV Diagnostic Test Product Overview
  • HRM-MS Based Companion Diagnostic Test
  • HRM-MS Based Companion Diagnostic Test Product Overview
  • Multiplexed Proteomic Assay - Alzheimer’s Disease
  • Multiplexed Proteomic Assay - Alzheimer’s Disease Product Overview
  • PD-L1 Blood Based Diagnostic Test
  • PD-L1 Blood Based Diagnostic Test Product Overview
  • PD-L1 Blood Based Diagnostic Test Clinical Trial
  • TAm-Seq NGS Lung Cancer Test
  • TAm-Seq NGS Lung Cancer Test Product Overview
  • VeriStrat - Breast Cancer
  • VeriStrat - Breast Cancer Product Overview
  • VeriStrat - Colorectal Cancer
  • VeriStrat - Colorectal Cancer Product Overview
  • Biodesix Inc - Key Competitors
  • Biodesix Inc - Key Employees
  • Biodesix Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Biodesix Inc, Recent Developments
  • Dec 16, 2022: Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors
  • Nov 03, 2022: Biodesix Announces Third Quarter 2022 Results and Highlights
  • Oct 20, 2022: Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
  • Oct 12, 2022: Biodesix to Present Data at the CHEST 2022 Annual Meeting
  • Oct 11, 2022: Biodesix Announces Preliminary Revenue for Third Quarter 2022
  • Aug 04, 2022: Biodesix Announces Second Quarter 2022 Results and Highlights
  • May 23, 2022: Integrated Dermatology partners With The Dermatology Center of Worcester to expand network in Massachusetts
  • May 11, 2022: Biodesix Announces First Quarter 2022 Results and Highlights
  • Apr 27, 2022: Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
  • Mar 14, 2022: Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights
  • Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Biodesix Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Biodesix Inc Pipeline Products by Equipment Type
  • Biodesix Inc Pipeline Products by Indication
  • Biodesix Inc Ongoing Clinical Trials by Trial Status
  • Biodesix Inc, Key Facts
  • Biodesix Inc, Major Products and Services
  • Biodesix Inc Number of Pipeline Products by Development Stage
  • Biodesix Inc Pipeline Products Summary by Development Stage
  • Biodesix Inc Ongoing Clinical Trials by Trial Status
  • Biodesix Inc Ongoing Clinical Trials Summary
  • 52-Gene Panel Based Companion Diagnostic - Product Status
  • 52-Gene Panel Based Companion Diagnostic - Product Description
  • AI-Based Algorithm - COVID-19 - Product Status
  • AI-Based Algorithm - COVID-19 - Product Description
  • Biodesix Collection Device - Product Status
  • Biodesix Collection Device - Product Description
  • Companion Diagnostic Test - NSCLC - Product Status
  • Companion Diagnostic Test - NSCLC - Product Description
  • HIV Diagnostic Test - Product Status
  • HIV Diagnostic Test - Product Description
  • HRM-MS Based Companion Diagnostic Test - Product Status
  • HRM-MS Based Companion Diagnostic Test - Product Description
  • Multiplexed Proteomic Assay - Alzheimer’s Disease - Product Status
  • Multiplexed Proteomic Assay - Alzheimer’s Disease - Product Description
  • PD-L1 Blood Based Diagnostic Test - Product Status
  • PD-L1 Blood Based Diagnostic Test - Product Description
  • PD-L1 Blood Based Diagnostic Test - A Study to Evaluate the Clinical Utility of Biomarkers, Including the Proteomic Primary Immune Response (PIR) Test, for Front-line Non-small Cell Lung Cancer (NSCLC) Patients Receiving Immunotherapy with and without the Addition of Systemic Platinum-based Chemotherapy who Have High Expression of Program Death Ligand-1 (PD-L1) on Their Tumor Cells
  • TAm-Seq NGS Lung Cancer Test - Product Status
  • TAm-Seq NGS Lung Cancer Test - Product Description
  • VeriStrat - Breast Cancer - Product Status
  • VeriStrat - Breast Cancer - Product Description
  • VeriStrat - Colorectal Cancer - Product Status
  • VeriStrat - Colorectal Cancer - Product Description
  • Biodesix Inc, Key Employees
  • Biodesix Inc, Subsidiaries
  • Glossary
List of Figures
  • Biodesix Inc Pipeline Products by Equipment Type
  • Biodesix Inc Pipeline Products by Development Stage
  • Biodesix Inc Ongoing Clinical Trials by Trial Status

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Cardiocom LLC
  • Foundation Medicine Inc
  • Roka Bioscience Inc
  • CardioDx Inc
  • Cardiocom LLC
  • Foundation Medicine Inc
  • Roka Bioscience Inc